Chai Discovery
Building frontier AI to engineer better molecules
San Francisco, United States · Founded 2024 · $200.0M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- chaidiscovery.com
- Total Funding
- $200.0M
- Last Round
- $130.0M Venture RoundDec 2025
- Rounds
- 2
About
Chai Discovery is an AI drug discovery company that develops foundation models for molecular biology, enabling the prediction and design of biochemical interactions with atomic precision. The company's flagship model, Chai-1 and Chai-2, are multi-modal foundation models for predicting molecular structures and de novo antibody design. Chai-2 achieves an 85% success rate in zero-shot antibody discovery. Founded in 2024 by former OpenAI researchers, Chai has partnered with Eli Lilly for AI-driven biologics discovery and raised $130M in a Series B led by General Catalyst. The company operates as a partner-facing R&D and software organization supporting biologics discovery for biopharma customers.
Summary
Chai Discovery is an Artificial Intelligence company based in San Francisco, United States, founded in 2024. It has raised $200.0M in total across 2 rounds, most recently a $130.0M Venture Round round in Dec 2025. Investors include Menlo Ventures.
Tech & App Stack
10 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
